Curevac N.V. buy Amped
Start price
22.06.21
/
0%
€50.88
Target price
17.06.22
-
Performance (%)
-72.98%
End price
18.06.22
€13.75
Summary
This prediction ended on 18.06.22 with a price of €13.75. The BUY prediction by Amped for Curevac N.V. performed very badly with a performance of -72.98%. This prediction was marked as speculative and is excluded from Amped's performance statistics.Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Curevac N.V. | 5.450% | 5.450% | - | - |
iShares Core DAX® | 0.347% | 2.173% | 18.599% | 21.611% |
iShares Nasdaq 100 | 0.715% | 0.138% | 26.542% | 40.349% |
iShares Nikkei 225® | 1.522% | 2.003% | 13.220% | 3.542% |
iShares S&P 500 | 0.631% | 1.633% | 25.009% | 42.942% |
According to Amped what are the pros and cons of Curevac N.V. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Fair valuation
EBIT growth >5% per year expected
Revenue growth >5% per year expected
Good culture
Differentiated customer and product portfolio
Well known brand
Small cyclical dependencies
Top 10 in its market
Capable Management
Very Future proof/growth oriented business model
Cons
Few uniques
Comments by Amped for this prediction
In the thread Curevac N.V. diskutieren
Buy Curevac N.V.
In the thread Trading Curevac N.v.
Die von Amped gewählte maximale Laufzeit wurde überschritten
Stopped prediction by Amped for Curevac N.V.
Curevac N.V.
Start price
Target price
Perf. (%)
€49.88
21.06.21
21.06.21
-
17.06.22
17.06.22
2.00%
22.06.21
22.06.21
Could be worthwhile Investment >10% per year
Fair valuation
EBIT growth >5% per year expected
Revenue growth >5% per year expected
Curevac N.V.
Start price
Target price
Perf. (%)
€48.56
17.06.21
17.06.21
-
17.06.22
17.06.22
2.73%
21.06.21
21.06.21
Could be worthwhile Investment >10% per year
Fair valuation
EBIT growth >5% per year expected
Revenue growth >5% per year expected